Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy - Wikidata - awgldk - TriplyDB

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

http://www.wikidata.org/entity/Q36349583

about

Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal CAR T Cell Therapy: A Game Changer in Cancer Treatment High-content molecular profiling of T-cell therapy in oncology Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults Biology and clinical application of CAR T cells for B cell malignancies Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds.Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy Driving CAR T-cells forward Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Fully human CD19-specific chimeric antigen receptors for T-cell therapy.Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients Chimeric antigen receptor-modified T cells strike back.CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.New development in CAR-T cell therapy.Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy.Adoptive Cell Therapy in Multiple Myeloma.An Update on the Use of Immunotherapy in the Treatment of Lymphoma.CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.Cancer Immunotherapy: Whence and Whither.Recent advances in T-cell immunotherapy for haematological malignancies.CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.Engineered T cells: the promise and challenges of cancer immunotherapy.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.Therapeutic targeting of splicing in cancer.Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.Peptide vaccines in cancer-old concept revisited.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

P2860

Q26744536-70CEC244-A8E7-4A29-949F-46A19513A26B Q26822769-1A1C4286-E508-401A-82AD-827963FD5079 Q28066792-B9AA1E52-9227-4493-B695-7AA27B177802 Q28072131-5F38B54A-5B6C-43AA-A9E7-BA6C7ACFF93E Q30827633-349EA1E2-A25E-4227-87EA-34FB7F713F4F Q33564364-1113D312-01B8-4A99-8481-FB9F2695194F Q33655754-F5CEE418-CBB7-4031-A0D0-8EF6B3772F0C Q33692070-16D83E2E-DF21-411B-A88A-D2CE0914B41E Q33827997-97921C97-C60C-457A-AC91-38B458D5E9D2 Q33907565-699AC86D-BB3A-4A11-AA4F-379E20D6B34F Q34046190-44BA9C57-592A-43D4-BD9A-84DF3D828AC3 Q34046263-009B7406-4746-4DC1-854A-008DF18323C6 Q34046505-65F9CC33-905E-422E-9445-95EF4F086D63 Q34517676-41506793-5C6D-4EEE-ABE7-44660534CCFC Q36281920-A1902FC6-8222-4DAB-9CEF-0E91ECC7DAE6 Q36651344-9149B9F3-CDF1-4C42-AD3A-A5C528DE9597 Q36951727-D285F50F-6C26-429B-8CD6-2ADDA34E78D1 Q37040370-21939F8B-FFEC-4E2C-B65C-B612B9AE0E5E Q37153598-655E2EED-54D6-4C49-9019-720F99661556 Q37322952-639E0C49-C347-4186-B7DD-A3274FE1AC91 Q37658246-E38CC131-95BA-4F6E-971F-60D3EB673299 Q38615436-50168ADD-98A2-4530-B655-8A8C9731343E Q38635138-270ABC14-E2D2-4013-90F7-7A9C4C469E82 Q38666304-CA3E737C-735D-47D7-90DB-E9C4E1D02754 Q38702393-D127A2E1-4DDD-489D-B17C-9EBB7BFD2F21 Q38737924-95FE51C9-A2D7-4CA6-B510-077B59DA0984 Q38789518-C76AEB3C-CE1D-4D06-9AED-E7145CE8C7BF Q38813257-8EC7B41E-B1D2-458D-A128-6A1DDE6EBA1C Q38823260-34585B98-FE24-438C-B660-F47A7AADFF7B Q38828829-820724C3-EFA8-4C23-BDAC-BCBDDD38B79B Q38913549-98F3C2D8-A691-42CF-A5B7-18F77ABD2D3F Q38945853-2A32DEB1-366A-4510-AE28-4862B3E120D2 Q38948363-97CEACF8-2C3F-47F8-AA05-2E96FBE42DB7 Q38957129-8367E580-1564-4348-8B93-0C0395A2716A Q39007364-E5DB49D1-570A-4125-8CE9-33B84DD899B3 Q39032901-AC157A05-A027-4184-BD66-0CF89A4D8ECA Q39035351-13A7AE83-C495-4243-9834-B45EA47D2CD4 Q39039017-C34D8FE2-0E7A-4AA9-BB56-DEC7F2AAA017 Q39059681-200E08AB-A2FB-4D3E-9EFE-D1834AAD51EB Q39130451-EEA08243-B3B1-45FB-971F-DB910DFB0BAF

P2860

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

http://www.wikidata.org/entity/Q36349583

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Convergence of Acquired Mutati ...... tance to CART-19 Immunotherapy

@ast

Convergence of Acquired Mutati ...... tance to CART-19 Immunotherapy

@en

type

label

Convergence of Acquired Mutati ...... tance to CART-19 Immunotherapy

@ast

Convergence of Acquired Mutati ...... tance to CART-19 Immunotherapy

@en

prefLabel

Convergence of Acquired Mutati ...... tance to CART-19 Immunotherapy

@ast

Convergence of Acquired Mutati ...... tance to CART-19 Immunotherapy

@en

P1433

Q36349583-97E9DF58-A91E-43ED-9EB8-06832830A4E2

P1476

Q36349583-DF3783E4-31E6-4D0D-A194-B55A4D0BA665

P2093

Q36349583-07E869C6-C240-4796-89A4-2320926CD5A0

Q36349583-0A6D5638-C552-4559-99CF-F07E00B6EEEA

Q36349583-1798A586-BD09-44F8-ACD4-A6F171B78D09

Q36349583-25C8FCC0-29F2-4913-A188-94066FBCB60B

Q36349583-2A714DA2-025F-4136-A1FD-AA44CCB0E5EF

Q36349583-2F9EDB34-13A9-4008-8605-D64AF4804867

Q36349583-57997DC6-81B8-4052-A939-99BFD6C8D699

Q36349583-615168B4-8225-4305-9872-D3133A7CE8EC

Q36349583-6C6E4995-D80F-4132-9A3F-00667D1F940C

Q36349583-80C728DD-B18A-46CF-B331-5EF9F5E557E9

P2860

Q36349583-003B376F-D2C3-4C43-94A6-0AB4CA197208

Q36349583-06C0C635-5611-40E6-A853-570E070C5E0F

Q36349583-09A0E0C9-B80D-4A7A-BB08-C508F236327A

Q36349583-0CCF4BF2-1054-4DCF-A352-CC5FD9324299

Q36349583-117A470B-1E78-4676-8596-FF874056B44B

Q36349583-147FDE46-EC13-4C8B-81EF-BBDBB6A4D6A3

Q36349583-19837136-7415-4F71-B768-A57C680AFFFB

Q36349583-22BEAE81-B98E-4CAF-B22D-F47C2F415D3C

Q36349583-28D870DB-E343-4800-A2E8-A3DE70931CA7

Q36349583-29BB97B4-B005-4A24-A159-5D8B16823AED

P304

Q36349583-F3E92A45-F331-4982-8D62-687EDA09E3D0

P31

Q36349583-AA7A7098-FAB2-4BDE-AA54-71AE7C661FEB

P356

Q36349583-F6387545-9FA5-4B1A-AF28-50F616324593

P433

Q36349583-E5F88E6B-A2CE-4438-B4F3-0D3F97ACB1C6

P478

Q36349583-CAA62465-C3BD-49BB-B4D7-1EB27D0144E4

P50

Q36349583-165C3AE6-6883-43BD-9B65-12902AA999A6

Q36349583-4A36638E-E1C2-4665-9B89-4C582434E2D8

Q36349583-6A564210-34D5-45CF-83CD-B848B3E44E04

Q36349583-809B7370-B0D8-46FA-97E2-15FE3FC1B12A

P577

Q36349583-F226E466-F574-4C19-B4F8-468B7EA882C2

P698

Q36349583-AE155B98-5662-4346-8A33-4D7C3A00B18D

P921

Q36349583-B9D58BAE-10C0-4EB7-8923-6157FC89BFDD

P932

Q36349583-F8C08861-40E2-4C8B-8B05-EFA52B8F45D4

P356

2159-8290.CD-15-1020

P1433

Cancer Discovery

P1476

Convergence of Acquired Mutati ...... tance to CART-19 Immunotherapy

@en

P2093

Alejandro Barrera

http://www.w3.org/2001/XMLSchema#string

Asen Bagashev

http://www.w3.org/2001/XMLSchema#string

Claudia Lanauze

http://www.w3.org/2001/XMLSchema#string

Colleen T Harrington

http://www.w3.org/2001/XMLSchema#string

Crystal Mackall

http://www.w3.org/2001/XMLSchema#string

David Allman

http://www.w3.org/2001/XMLSchema#string

David M Barrett

http://www.w3.org/2001/XMLSchema#string

Derek Oldridge

http://www.w3.org/2001/XMLSchema#string

Elad Jacoby

http://www.w3.org/2001/XMLSchema#string

Elaine Y Chung

http://www.w3.org/2001/XMLSchema#string

P2860

AVISPA: a web tool for the prediction and analysis of alternative splicing

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Targeting the B-cell receptor signaling pathway in B lymphoid malignancies

Chromatin and epigenetic regulation of pre-mRNA processing

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis

STAR: ultrafast universal RNA-seq aligner

GenBank: update

P304

1282-1295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-15-1020

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Andrei Thomas-Tikhonenko

Robyn T Sussman

Nicole M Martinez

P577

2015-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26516065

http://www.w3.org/2001/XMLSchema#string

P921

P932

4670800

http://www.w3.org/2001/XMLSchema#string